Ultragenyx Pharmaceutical Inc.

04/30/2024 | Press release | Distributed by Public on 04/30/2024 06:05

Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.